How to buy Certara (CERT) stock when it goes public

Certara, headquartered in Princeton, NJ, produces model-based pharmaceutical software.

What we know about the Certara IPO

Certara, which uses modeling to optimize the drug-development process, is raising at least $100 million in an initial public offering, according to a filing with the Securities and Exchange Commission. The company could, however, raise as much as $500 million in the IPO.

No closing date has been set. After the IPO, shares will trade on the Nasdaq under "CERT." The IPO is being offered through Jefferies, William Blair, Morgan Stanley, Barclays, Credit Suisse and BofA Securities.

How to buy shares in Certara when it goes public

Once Certara goes public, you'll need a brokerage account to invest. Consider opening a brokerage account today so you're ready as soon as the stock hits the market.

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Certara. Find the stock by name or ticker symbol: CERT. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy immediately with a market order or use a limit order to delay your purchase until Certara reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Certara, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Certara. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

Mobile users

Moomoo

Our top pick for

Building a portfolio

Sofi Invest

Our top pick for

Large investments

Vanguard

How do similar companies perform?

It's impossible to predict how any stock will perform — and IPOs can be particularly volatile. But evaluating the performance of companies like Certara can be useful in determining how the market is performing and whether now is a good time to invest in this industry. Select a company to learn more about what they do and how their stock performs, including market capitalization, the price-to-earnings (P/E) ratio, price/earnings-to-growth (PEG) ratio and dividend yield. While this list includes a selection of the most well-known and popular stocks, it doesn't include every stock available.

• Schrödinger (SDGR.US)

  Company summary

  Schrödinger, Inc. provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. The company operates through two segments, Software and Drug Discovery. Its segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment develops a pipeline of preclinical and clinical drug discovery programs through its computational platform in collaboration with pharmaceutical companies. Schrödinger, Inc. has strategic collaborations with Twist Bioscience Corporation; Thermo Fisher Scientific to extend the use of cryo-EM in connection within silico compound screening to accelerate drug discovery; and Bristol Myers Squibb Company to discover, develop, and commercialize therapeutics in multiple disease areas. The company was founded in 1990 and is based in New York.

  Historical performance

  Stock information

  • Market capitalization: $4836302336
  • P/E ratio: -99999.99
  • Dividend yield: N/A%

  Get more detailed information and learn how to buy SDGR.US stock

• Simulations Plus (SLP.US)

  Company summary

  Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California.

  Historical performance

  Stock information

  • Market capitalization: $1116175232
  • P/E ratio: 112
  • PEG ratio: 6.5392
  • Dividend yield: 0.0043%

• Thermo Fisher Scientific (TMO.US)

  Company summary

  Thermo Fisher Scientific Inc. provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of new drugs and vaccines, and diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; blood-test systems and antibody tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; cancer diagnosis and medical research products; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, and ultralow-temperature freezers and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics and chemicals; and pharma services. It has collaboration with WuXi Diagnostics and Mayo Clinic to develop antibodies tests; a strategic collaboration with Schrödinger, Inc. to expand structure-based drug discovery to novel targets using Cryo-EM; and an agreement with Daiichi Sankyo to co-develop a companion diagnostic. The company was incorporated in 1956 and is headquartered in Waltham, Massachusetts.

  Historical performance

  Stock information

  • Market capitalization: $184071520256
  • P/E ratio: 50.2771
  • PEG ratio: 1.8516
  • Dividend yield: 0.0019%

  Get more detailed information and learn how to buy TMO.US stock

Compare trading platforms

Sort by:

Name	Product	Stock trade fee	Asset types	Option trade fee	Annual fee
Vanguard		$0	Stocks, Mutual funds, ETFs, Forex	$1	$20 per year	Get a personal advisor when you open an account with at least $50,000.	Go to site More Info		loading Fetching your data...
Sofi Invest		$0	Stocks, ETFs, Cryptocurrency	N/A	0%	A free way to invest in stocks, ETFs and crypto.	Go to site More Info		loading Fetching your data...
Robinhood		$0	Stocks, Options, ETFs, Cryptocurrency	$0	0%	Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.	Go to site More Info		loading Fetching your data...
Interactive Brokers		$0	Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash	$0 + $0.65/contract, $1 minimum	0%	IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.	Go to site More Info		loading Fetching your data...
TD Ameritrade		$0 or $25 broker-assisted	Stocks	$0 + $0.65/contract, or $25 broker-assisted		TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.	Go to site More Info		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare